Table 2.
Selected recent/ongoing trials of NK-based adoptive therapy of cancer.
| Identifier | Trial | Status | Phase | NK cells/drug | Tumor |
|---|---|---|---|---|---|
| NCT00900809 | QUILT-3.018: Neukoplast™ (NK-92) for the treatment of refractory or relapsed acute myeloid leukemia | Recruitment completed | I | NK-92 | Acute myeloid leukemia |
| NCT03027128 | QUILT-3.028: study of haNK™ for infusion in subjects with metastatic or locally advanced solid tumors | Recruitment completed | I | NK-92 | Solid tumor |
| NCT03383978 | Intracranial injection of NK-92/5.28.z cells in patients with recurrent HER2-positive glioblastoma (CAR2BRAIN) | Recruiting | I | NK-92/5.28.z | Glioblastoma |
| NCT02573896 | Immunotherapy of relapsed refractory neuroblastoma with expanded NK cells | Recruiting | I | CAR-NK-Ch14.18 lenalidomide | Neuroblastoma |
| NCT02280525 | Cord blood Natural Killer (NK) cells in leukemia/lymphoma | Active, not recruiting | I | NK Cells, lenalidomide, rituximab (anti-CD20), fludarabine, cyclophosphamide, cytarabine | Leukemia |
| NCT02481934 | Clinical trial of expanded and activated autologous NK cells to treat multiple myeloma (NK-VS-MM) | Completed | I | NK Cells, lenalidomide, bortezomib | Multiple myeloma |
| NCT03415100 | Pilot study of NKG2D-ligand targeted CAR-NK cells in patients with metastatic solid tumors | Recruiting | I | CAR-NK cells targeting NKG2D ligands | Solid tumors |
| NCT01974479 | Pilot study of redirected haploidentical natural killer cell infusions for B-lineage acute lymphoblastic leukemia | Suspended | I | Anti-CD19 redirected NK cells | B-cell acute lymphoblastic leukemia |
| NCT03579927 | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced cord blood NK cells, high-dose chemotherapy, and stem cell transplant in treating participants with B-cell lymphoma | Not yet recruiting | I/II | Cord blood-NK Cells Autologous HSCT carmustine Cytarabine, etoposide, filgrastim, melphalan, rituximab (anti-CD20) | CD19 positive, mantle cell lymphoma, recurrent diffuse large B-cell lymphoma, recurrent follicular lymphoma, refractory B-cell non-Hodgkin lymphoma, refractory diffuse large B-Cell lymphoma, refractory follicular lymphoma |
| NCT03056339 | Umbilical and Cord Blood (CB) derived CAR-engineered NK cells for B lymphoid malignancies | Recruiting | I/II | iC9/CAR.19/IL15 transduced CB-NK Cells, fludarabine, cyclophosphamide, mesna, AP1903 | B-lymphoid malignancies, acute lymphocytic leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma |
| NCT02839954 | CAR-pNK cell immunotherapy in MUC1 positive relapsed or refractory solid tumor | Unknown | I/II | Anti-MUC1 CAR-NK cells | Hepatocellular carcinoma, NSCLc, pancreatic carcinoma, triple-negative invasive breast carcinoma, malignant glioma of brain, colorectal carcinoma, gastric carcinoma |
| NCT02892695 | PCAR-119 bridge immunotherapy prior to stem cell transplant in treating patients with CD19 positive leukemia and lymphoma | Unknown | I/II | Anti-CD19 CAR-NK cells | Acute/chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, B-cell prolymphocytic leukemia, diffuse large cell lymphoma |
| NCT02742727 | CAR-pNK cell immunotherapy in CD7 positive leukemia and lymphoma | Unknown | I/II | Anti-CD7 CAR-NK cells | Acute myeloid leukemia, precursor T-cell lymphoblastic leukemia-lymphoma, T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, extranodal NK/T-cell lymphoma, nasal type enteropathy-type intestinal T-cell lymphoma |